

# **Risk of adverse COVID-19 outcomes for people living with HIV: a rapid review and meta-analysis**

**Running head:** HIV & COVID-19 outcomes: review & meta-analysis

**Authors:** Maya M. MELLOR<sup>1</sup>, Anne C. BAST<sup>1</sup>, Nicholas R. JONES<sup>2</sup>, Nia W. ROBERTS<sup>3</sup>, José M. ORDÓÑEZ-MENA<sup>2,6</sup>, Alastair J.M. REITH<sup>1</sup>, Christopher C. BUTLER<sup>2</sup>, Philippa C. MATTHEWS<sup>4,5</sup>, Jienchi DORWARD<sup>2,7</sup>

**Affiliations:**

1: Medical Sciences Division, University of Oxford, Oxford, UK

2: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

3: Outreach Librarian Knowledge Centre, Bodleian Health Care Libraries, Oxford, UK

4: Nuffield Department of Medicine, University of Oxford, Oxford, UK

5: Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

6: NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

7: Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa

**Corresponding author:** Jienchi Dorward, Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford OX2 6GG, United Kingdom, [jienchi.dorward@phc.ox.ac.uk](mailto:jienchi.dorward@phc.ox.ac.uk)

**Requests for reprints:** Jienchi Dorward, Radcliffe Primary Care Building, Nuffield  
Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, Woodstock Rd,  
Oxford OX2 6GG, United Kingdom, [jienchi.dorward@phc.ox.ac.uk](mailto:jienchi.dorward@phc.ox.ac.uk)

Funding: This work was supported by funding from the Wellcome Trust (216421/Z/19/Z).

**Word count: 2498/2500**

## **Abstract: (250/250 words)**

**Objective:** To assess whether people living with HIV (PLWH) are at increased risk of COVID-19 mortality or adverse outcomes, and whether antiretroviral therapy (ART) influences this risk.

**Design:** Rapid review with meta-analysis and narrative synthesis.

**Methods:** We searched databases including Embase, Medline, medRxiv, and Google Scholar up to 26<sup>th</sup> August 2020 for studies describing COVID-19 outcomes in PLWH and conducted a meta-analysis of higher quality studies.

**Results:** We identified 1,908 studies and included 19 in the review. In a meta-analysis of five studies, PLWH had a higher risk of COVID-19 mortality (hazard ratio (HR) 1.93, 95% Confidence Interval (CI): 1.59-2.34) compared to people without HIV. Risk of death remained elevated for PLWH in a subgroup analysis of hospitalised cohorts (HR 1.54, 95% CI: 1.05-2.24) and studies of PLWH across all settings (HR 2.08, 95%CI: 1.69-2.56). Eight other studies assessed the association between HIV and COVID-19 outcomes, but provided inconclusive, lower-quality evidence due to potential confounding and selection bias.

There were insufficient data on the effect of CD4+ T cell count and HIV viral load on COVID-19 outcomes. Eleven studies reported COVID-19 outcomes by ART-regimen. In the two largest studies, tenofovir-disoproxil-fumarate (TDF)-based regimens were associated with a lower risk of adverse COVID-19 outcomes, although these analyses are susceptible to confounding by comorbidities.

**Conclusion:** Evidence is emerging that suggests a moderately increased risk of COVID-19 mortality amongst PLWH. Further investigation into the relationship between COVID-19 outcomes and CD4+ T cell count, HIV viral load, ART and the use of TDF is warranted.

**Keywords:** HIV; AIDS; COVID-19; SARS-CoV-2; Antiretroviral therapy

## **Introduction:**

By September 2020, over 30 million people worldwide had been diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1]. Although SARS-CoV-2 infection may be asymptomatic or cause only mild symptoms, a proportion of people develop severe coronavirus disease 2019 (COVID-19), leading to hospitalisation, acute respiratory distress syndrome or death. Established risk factors for severe COVID-19 among the general population include older age, chronic kidney disease and obesity [2].

People living with HIV (PLWH), who constitute approximately 0.5% of the global population [3], may have an increased risk of adverse outcomes from COVID-19 as a result of HIV-associated immune dysfunction [4]. There may also be a higher prevalence of comorbidities amongst PLWH that predispose to unfavourable COVID-19 outcomes [5].

Some antiretroviral agents are under consideration as potential treatments for COVID-19 [6], but the influence of antiretroviral therapy (ART) on COVID-19 outcomes is not known. In this rapid review, we aim to evaluate the evidence regarding the risk of adverse COVID-19 outcomes in PLWH, and the extent to which this risk is modified by other factors including ART.

## **Methods:**

We used rapid review methods to identify studies between 1st January and 26th August 2020 that described COVID-19 outcomes in PLWH and compared outcomes with HIV-negative people or the general population, or that compared outcomes by risk factors amongst PLWH.

We searched Embase, Medline, medRxiv, LitCovid, Trip, Google and Google Scholar without language restrictions. Search terms are available in Table S1. One author with extensive literature search expertise performed the initial screen to exclude duplicates and studies not related to HIV. For remaining articles, one author performed title and abstract

screening, with subsequent full text review by two authors using a standardised data extraction form. Disagreements were resolved by a third author. We included pre-prints in order to capture emerging evidence. Studies with  $\leq 15$  participants were excluded as they were unlikely to be powered to detect meaningful associations. We critically appraised the quality of studies using checklists for Case Series and for Cohort Studies from the Joanna Briggs Institute [7].

Cohort studies reporting COVID-19-related death in people with and without HIV that adjusted for age, sex and comorbidities were included in a meta-analysis. Cohort-specific relative risks (RRs) and hazard ratios (HRs) were combined with random effects model to account for variability of the true effect between studies. HRs and RRs numerically approximate each other with shorter follow-up, rarer endpoints, and risks closer to 1 [8]. Subgroup analyses were conducted by study setting and method of confounder adjustment. Meta-analysis was performed in R (version 3.6.0) using the *meta* package [9].

## **Results:**

### **Summary of included studies**

We identified 1,908 records and included 19 studies in our final qualitative analysis (Figure 1). Seventeen studies [10–26] were peer-reviewed and two were preprints [27,28]. Quality appraisal is included in Tables 1, S2 and S3.

We identified five cohort studies (two prospective, three retrospective) comparing COVID-19 related mortality between PLWH and HIV-negative people, which we pooled in a meta-analysis [10,16,18,27,28]. Four of these reported all-cause mortality among people diagnosed with COVID-19 [10,16,18,28] and one reported mortality due to COVID-19 as recorded on death certificates [27]. Of the remaining fourteen studies, seven made multiple comparisons between PLWH with COVID-19 and HIV-negative cohorts, and/or the general population,

and/or PLWH without COVID-19, [11,12,14,15,23,25,26], two studies compared only to a HIV-negative cohort [13,19], two studies compared only cohorts of PLWH with and without COVID-19 [17,22] and three studies compared only the characteristics of PLWH with different COVID-19 disease severity [20,21,24].

There were ten studies that included a total of >1,000 individuals, but amongst these the median number of PLWH with COVID-19 co-infection was only 55 (interquartile range 35-115). Seventeen of the studies were performed in high-income countries and most included a majority of patients on ART with well-controlled HIV (Table 1).

### **Quality of evidence and risk of bias assessment**

There were common limitations among the included studies. Most were retrospective analyses of routinely-collected clinical data, meaning identification of COVID-19 cases was not systematic and depended on the local approach to screening and diagnosis. This has varied over time and between settings, and may also differ between PLWH and the general population. Only five studies directly compared COVID-19 outcomes amongst PLWH and HIV-negative people in the same cohort, and accounted adequately for potential confounding by co-morbidities associated with adverse COVID-19 outcomes. Other studies used inadequately matched HIV-negative controls, or the general population, which is susceptible to bias as the exposed and control groups were selected differently. Across all studies, the numbers of PLWH and COVID-19 infection were relatively low.

### **Adjusted analyses of HIV and risk of death in COVID-19:**

In a meta-analysis of five cohort studies which accounted for confounding, the risk of death from COVID-19 for PLWH was almost double that of HIV-negative people (HR=1.93, 95% confidence interval [CI] 1.59-2.34) (Figure 1) [10,16,18,27,28]. Three of these studies used large routine databases to identify PLWH across community and hospital settings, in South

Africa [18], the United Kingdom (UK)[27] and United States of America (USA)[10], and two studies were limited to hospitalised PLWH and COVID-19 in the UK [28] and USA [16]. In a subgroup analysis there was no significant difference between study settings ( $p=0.17$ ), although a weaker HR was seen in hospitalised patients (Figure S1). Among the three studies which used multivariable adjustment to account for confounding [18,27,28], the *crude* risk of COVID-19 death was similar between people with and without HIV, but after adjustment for age, the adjusted risk amongst PLWH was higher. Subsequent adjustment for comorbidities did not drastically alter HRs (Table 1). In sub-group analysis by method of accounting for confounders, a weaker HR was seen in the smaller two studies which used propensity score matching (Figure S2) [10,16].

### **Adjusted analyses of risk of hospitalisation and morbidity in PLWH:**

Three of the five cohort studies conducted analyses of the association between HIV status and the risk of other COVID-19 outcomes [10,16,28]. Amongst 47,539 individuals hospitalised with COVID-19 in the UK, the odds of critical care admission was higher among the 115 PLWH (odds ratio (OR) 2.60, 95 % CI 1.74-3.87), but this was attenuated after adjustment for demographics and co-morbidities (aOR 1.13, 95% CI 0.72-1.75) [28]. In the analysis of 50,167 people with COVID-19 in the USA, 404 PLWH ( $n=404$ ) were at increased risk of hospitalisation compared to 1:1 propensity score matched HIV-negative controls (RR 1.70, 95% CI: 1.21-2.38) [10]. Lastly, among 2,638 people hospitalised with COVID-19 in the USA, there were 6 (28.6%) intensive care unit admissions among 21 PLWH, compared to 7 (16.7%) amongst a propensity score matched cohort of 42 HIV negative people ( $p = 0.271$ )[16].

### **Unadjusted analyses of COVID-19 related outcomes in PLWH:**

Eight studies provided lower-quality evidence regarding COVID-19 outcomes in PLWH as they did not compare HIV-positive and negative people in the same cohort, or did not adequately account for confounders. The largest of these was a Spanish multi-centre study of 77,590 PLWH, of whom 236 were diagnosed with COVID-19 and 20 died. In keeping with our meta-analysis result, age- and sex-standardised mortality from COVID-19 were found to be higher in PLWH (3.7 per 10,000) compared to the general population (2.1 per 10,000) [11]. The other seven studies [12–15,19,25,26] were limited due to being at single sites, having small sample sizes (median 64, range n=31-161 PLWH diagnosed with COVID-19) and not accounting for potential confounding. These studies report conflicting results with one suggesting a higher rate of hospitalisation and mortality among PLWH compared to the general COVID-19-positive population [12], two studies suggesting lower COVID-19 mortality in PLWH [14,25] and four studies reporting no significant difference in the risk of adverse outcomes from COVID-19 between PLWH and HIV-negative cohorts [13,19] or the general population [15,26].

### **Risk of death and hospitalisation in relation to CD4+ T cell count and HIV viral load:**

Several of the large cohort studies did not include data on CD4+ T cell count or HIV viral loads [10,27,28]. In the South African study, lower CD4+ T cell counts (measured during the COVID-19 episode) were associated with mortality, but this could be a result of, rather than causing, severe disease (Table 2). There was no difference in outcomes by HIV viral load, although viral load data was incomplete and numbers with unsuppressed viral loads were small [18]. A London HIV clinic found that 18 PLWH who were hospitalised with COVID-19 had a lower median CD4+ T cell count (395 vs 573 cells/ $\mu$ L,  $p=0.03$ ) compared to their 2,699 PLWH outpatients (Table 2) [17]. A further nine studies (median n= 54 PLWH and



COVID-19, range n=35-93) found no significant association between CD4+ T cell count or HIV viral load and COVID-19 outcomes [13,14,16,20–24,26].

### **Impact of ART regimen on COVID-19 outcomes:**

No studies compared COVID-19 outcomes between PLWH receiving and not receiving ART. We identified eleven studies assessing the relationship between specific ART regimens and COVID-19 outcomes in PLWH. In South Africa, COVID-19 related mortality was lower in patients on TDF-based regimens versus abacavir/zidovudine-based regimens, which are used for patients with co-morbidities or requiring second line treatment (aHR: 0.42; 95% CI: 0.22-0.78) [18]. While this analysis was adjusted for certain co-morbidities, the observed association may be confounded due to patients receiving TDF having less complex healthcare needs. In the Spanish multi-centre study, PLWH receiving TDF and emtricitabine (FTC) had the lowest risk for COVID-19 diagnosis (16.9 per 10,000) and hospitalisation (10.5 per 10,000) compared to all other ART regimens investigated, but without adjusting for co-morbidities [11]. A US hospital study found that PLWH and COVID-19 who survived were more likely to have been treated with NRTIs than those PLWH who died (99% vs 89%,  $p=0.04$ ) in univariate analysis [13]. Seven smaller studies (n=18-93 PLWH with COVID-19) reported no significant association between ART-regimen and COVID-19 severity amongst PLWH [14,15,17,20–24].

### **Other factors influencing COVID-19 outcomes among PLWH:**

Thirteen studies assessed the influence of comorbidities and demographics on the outcomes of COVID-19 amongst PLWH [13,14,16–18,20–24,26–28]. In the UK-based cohort study of hospitalised patients, among 115 PLWH with COVID-19, the 26 who died were more likely to have obesity and diabetes [28]. Bhaskaran et al and Childs et al report evidence of a higher risk of COVID-19 death and hospitalisation respectively amongst PLWH of black ethnicity

(Bhaskaran et al mortality aHR=3.80; 95% CI: 2.15-6.74, p for interaction=0.045; Childs et al hospitalisation crude OR: 12.22, 95% CI: 1.62-92.00) [17,27]. Other smaller analyses suggested that amongst PLWH, factors such as older age [23], metabolic disorders [23], obesity [14], African ethnicity [23] and organ transplantation [13] were associated with COVID-19 infection or severity.

## **Discussion:**

### **Summary**

Emerging evidence suggests an increased risk of COVID-19 related death in PLWH. There was insufficient data to determine whether HIV viral load, CD4+ T cell counts or ART use are associated with COVID-19 related death. We found some evidence that among PLWH receiving ART, TDF use may be associated with lower frequency of SARS-CoV-2 infection and milder courses of COVID-19, although this was not consistent between studies and was susceptible to confounding. Risk factors for severe COVID-19 among PLWH include older age, obesity and black ethnicity, and appear similar to the general population.

### **Risk of COVID-19 related mortality among PLWH**

In our review, the two population-based studies from South Africa and the UK both suggested almost double the risk of COVID-19 related death amongst PLWH, despite having very different demographic profiles [18,27]. In contrast, studies restricted to cohorts of PLWH diagnosed with COVID-19 [10], and hospitalised patients with COVID-19 [16,28] found a weaker or null effect. These studies are more at risk of selection bias, as PLWH with milder symptoms may be more likely to test for SARS-CoV-2 or be hospitalised by clinicians (due to a higher perceived risk), compared to people without HIV who may only be tested or hospitalised once more severely unwell. This would lead to the cohort of PLWH being less unwell at baseline compared to the HIV negative cohort, leading to underestimation of any

association between HIV status and COVID-19 related mortality. Furthermore, studies restricted to hospitalised patients cannot account for the effect of HIV (or any other potential risk factor) on SARS-CoV-2 infection and COVID-19 severity which result in hospitalisation, and therefore may underestimate the effect of risk factors on COVID-19 death, compared to studies in the general population [29].

### **Influence of ART**

We found no evidence to determine whether ART reduces COVID-19 severity through immune reconstitution, as most studies included PLWH on ART. Regarding specific antiretrovirals, the potential therapeutic value of TDF for COVID-19 is supported by results from molecular docking studies [30]. However, TDF is relatively contra-indicated in renal impairment [31], meaning patients receiving TDF-based ART are likely to have less comorbidities, which may explain the observed better COVID-19 outcomes. Randomised trials of TDF prophylaxis for SARS-CoV-2 are underway [32].

### **Comparisons with existing literature**

PLWH are known to be at higher risk of respiratory bacterial infections, but the evidence regarding acute viral infections is less clear [33]. A review from the H1N1 influenza pandemic in 2009/2010 found some evidence of a higher risk of adverse H1N1 outcomes amongst PLWH who were severely immunocompromised [34]. However, the quality of the evidence was weak with a lack of rigorously-designed prospective cohort studies, reflecting the challenges of in-pandemic research [34].

As of August 26<sup>th</sup> 2020, we identified seven systematic reviews on COVID-19 in PLWH [35–41]. All these reviews lacked the more robust evidence from recent large cohort studies [18,27,28]. Moreover, one review included articles assessing non-HIV related immunodeficiency [38] and four did not address the influence of ART [35,39–41].

## **Limitations**

Our meta-analysis of five studies is potentially limited by the small numbers of PLWH with COVID-19 who died. This presented challenges when accounting for confounding; studies that used multivariable analyses to adjust for confounding were susceptible to over-fitting of models and potential over-adjustment by factors which could be on the causal pathway between HIV and death (e.g. malignancy or tuberculosis). Studies that used matching were potentially under-powered, which may explain why they tended to report no independent association between HIV and COVID-19 death. In our narrative synthesis, the majority of the studies were small case series or cohort studies that did not adequately account for confounders such as age. Most were performed in high-income countries, and the majority of participants had well-controlled HIV on ART. This may limit the applicability to populations of PLWH in other settings. Only 68% of adults and 53% of children living with HIV globally are receiving ART [42], highlighting a crucial need to examine the risk of COVID-19 complications in these populations.

## **Conclusion:**

We present evidence which suggests a moderately increased risk of COVID-19 death among PLWH. TDF-based ART may be associated with lower risk of COVID-19 diagnosis and adverse outcomes, although this finding is susceptible to confounding. Measures to mitigate COVID-19 risk among PLWH should be included in the global pandemic response, while further research into the role of ART, immunosuppression and viral suppression is needed to quantify and address risks for PLWH in diverse settings.

## **Acknowledgements:**

MM, NJ and JD conceived the study. NR performed the literature search. MM and AB contributed equally to the screening and qualitative analysis, with support from NJ and JD. JOM performed the meta-analysis. MM and AB wrote the first draft of the manuscript. MM, AB, NR, JOM, AR, CB, PM, NJ and JD critically reviewed and edited the manuscript and consented to publication.

## **Conflicts of Interest and Source of Funding:**

There are no conflicts of interest to declare. NJ and JD are funded by the Wellcome Trust PhD Programme for Primary Care Clinicians (216421/Z/19/Z).

## References

- 1 World Health Organization (WHO). **Weekly Operational Update on COVID-19, 21 August 2020**. 2020; :1–10.
- 2 Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, *et al*. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. *JAMA Netw. open*. 2020. doi:10.1001/jamanetworkopen.2020.12270
- 3 World Health Organ. HIV/AIDS. 2020.
- 4 Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, *et al*. **OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients**. *medRxiv* 2020; :2020.05.06.20092999.
- 5 Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. **The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective**. *AIDS Behav* Published Online First: 2020. doi:10.1007/s10461-020-02871-9
- 6 Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. **Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review**. *JAMA - J Am Med Assoc* 2020; **323**:1824–1836.
- 7 Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, *et al*. **Methodological quality of case series studies**. *JBISRIR-D-19-00099 Reports* Published Online First: 2019. doi:10.11124/JBISRIR-D-19-00099
- 8 Symons MJ, Moore DT. **Hazard rate ratio and prospective epidemiological studies**. *J Clin Epidemiol* Published Online First: 2002. doi:10.1016/S0895-4356(02)00443-2

- 9 Schwarzer G. **Package “meta” Title General Package for Meta-Analysis.** *R News*  
Published Online First: 2007. doi:10.1007/978-3-319-21416
- 10 Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. **Characteristics and outcomes of COVID-19 in patients with HIV: a multi-center research network study.** *AIDS*  
Published Online First: 2020. doi:10.1097/QAD.0000000000002666
- 11 del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, *et al.* **Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy.** *Ann Intern Med* Published Online First: 2020. doi:10.7326/m20-3689
- 12 Härter G, Spinner CD, Roeder J, Bickel M, Krznaric I, Grunwald S, *et al.* **COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.** *Infection* Published Online First: 2020. doi:10.1007/s15010-020-01438-z
- 13 Sigel K, Swartz T, Golden E, Paranjpe I, Somani S, Richter F, *et al.* **Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City.** *Clin Infect Dis* Published Online First: 2020. doi:10.1093/cid/ciaa880
- 14 Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Drona F, *et al.* **Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort.** *Lancet HIV* Published Online First: 2020. doi:10.1016/s2352-3018(20)30164-8
- 15 Shalev N, Scherer M, LaSota ED, Antoniou P, Yin MT, Zucker J, *et al.* **Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019.** *Clin Infect Dis* 2020; **24**:23–26.
- 16 Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, *et al.* **Outcomes among HIV-positive patients hospitalized with COVID-19.** *J Acquir*

- Immune Defic Syndr* Published Online First: 2020.  
doi:10.1097/QAI.0000000000002423
- 17 Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E, Quinn K, *et al.* **Hospitalized Patients With COVID-19 and Human Immunodeficiency Virus: A Case Series.** *Clin Infect Dis* 2020; :1–2.
- 18 Boulle A, Davies M-A, Hussey H, Ismail M, Morden E, Vundle Z, *et al.* **OUP accepted manuscript.** *Clin Infect Dis* Published Online First: 2020.  
doi:10.1093/cid/ciaa1198
- 19 Miyashita H, Kuno T. **Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV infection in New York City.** *HIV Med* Published Online First: 2020. doi:10.1111/hiv.12920
- 20 Ho H, Peluso MJ, Margus C, Lopes JPM, He C, Gaisa MM, *et al.* **Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV.** *Infect Dis Soc Am* Published Online First: 2020. doi:10.1080/1059924X.2017.1319315
- 21 Di Biagio A, Ricci E, Calza L, Squillace N, Menzaghi B, Rusconi S, *et al.* **Factors associated with hospital admission for COVID-19 in HIV patients .** *AIDS* Published Online First: 2020. doi:10.1097/QAD.0000000000002663
- 22 Maggiolo F, Zoboli F, Arosio M, Valenti D, Guarneri D, Sangiorgio L, *et al.* **SARS-CoV-2 infection in persons living with HIV: a single center prospective cohort.** *J Med Virol* 2020; :0–2.
- 23 Etienne N, Karmochkine M, Slama L, Pavie J, Batisse D, Usubillaga R, *et al.* **HIV infection and COVID-19.** *Aids* 2020; **Publish Ah.**  
doi:10.1097/qad.0000000000002651
- 24 Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, *et al.*



- Clinical characteristics, risk factors, and incidence of symptomatic COVID-19 in adults living with HIV.** *Aids* 2020; **Publish Ah.** doi:10.1097/qad.0000000000002643
- 25 Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, *et al.* **Clinical features and outcomes of HIV patients with coronavirus disease 2019.** *Clin Infect Dis* Published Online First: 2020. doi:10.1093/cid/ciaa579
- 26 Huang J, Xie N, Hu X, Yan H, Ding J, Liu P, *et al.* **Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City: A population-based cohort study.** *Infect Dis Soc Am* Published Online First: June 2020. doi:10.1016/j.euroneuro.2016.03.007
- 27 Bhaskaran K, Ct R, Mackenna B, Schultz A, Mehrkar A, Bates C, *et al.* **HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform (\* Joint principal investigators ) Faculty of Epidemiology and Population Health , London Sc.** 2020.
- 28 Geretti AM, Stockdale AJ, Kelly SH, Collins S, Waters L, Villa G, *et al.* **Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC 2 WHO Clinical Characterisation Protocol UK Protocol: prospective observational study.** 2020.
- 29 Griffith G, Morris TT, Tudball M, Herbert A, Mancano G, Pike L, *et al.* **Collider bias undermines our understanding of COVID-19 disease risk and severity.** *medRxiv* Published Online First: 2020. doi:10.1101/2020.05.04.20090506
- 30 Elfiky AA. **Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.** Published Online First: 2020. doi:10.1016/j.lfs.2020.117592

- 31 Venter WDF, Fabian J, Feldman C. **An overview of tenofovir and renal disease for the HIV-treating clinician.** *South Afr J HIV Med* 2018; **19**:1–8.
- 32 Polo R, Hernán M. Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS). ClinicalTrials.gov. 2020.<https://clinicaltrials.gov/ct2/show/NCT04334928> (accessed 19 Sep2020).
- 33 Benito N, Moreno A, Miro JM, Torres A. **Pulmonary infections in HIV-infected patients: An update in the 21st century.** *Eur Respir J* 2012; **39**:730–745.
- 34 Sheth AN, Althoff KN, Brooks JT. **Influenza susceptibility, severity, and shedding in HIV-infected adults: A review of the literature.** *Clin Infect Dis* 2011; **52**:219–227.
- 35 Baluku JB, Olum R, Agolor C, Nakakande J, Russell L, Bongomin F, *et al.* **Prevalence, clinical characteristics and treatment outcomes of HIV and SARS-CoV-2 co-infection: a systematic review and meta-analysis.** *medRxiv* 2020; :2020.05.31.20118497.
- 36 Masukume G, Mapanga W, Zyl DS van. **COVID-19 and HIV co-infection: a living systematic evidence map of current research.** *medRxiv* 2020; :2020.06.04.20122606.
- 37 Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. **Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.** *J Int AIDS Soc* 2020; **23**:1–9.
- 38 Gao Y, Chen Y, Liu M, Shi S, Tian J. **Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis.** *J Infect* 2020; **81**:e93–e95.
- 39 Mirzaei H, McFarland W, Karamouzian M, Sharifi H. **COVID-19 Among People**

**Living with HIV: A Systematic Review.** *AIDS Behav* Published Online First: 2020.

doi:10.1007/s10461-020-02983-2

40 Cooper TJ, Woodward BL, Alom S, Harky A. **Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review.** *HIV Med* 2020; :1–11.

41 Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, *et al.*

**AIDS Prevalence of HIV in patients hospitalized for COVID-19 and associated outcomes: a systematic review and meta-analysis-Manuscript Draft-Manuscript**

**Number: Full Title: Prevalence of HIV in patients hospitalized for COVID-19**

**and associated outcomes: a . medRxiv** 2020; :2020.07.03.20143628.

42 World Health Organisation. **HIV/AIDS Fact Sheet.**

## Tables

Table 1: Details of all included studies with summary of mortality findings and quality appraisal

| Study details  | Location                                 | Study type and study population  | Characteristics of PLWH  | Mortality  | Quality appraisal*   |
|--|--|--|--|--|--|
| <b>STUDIES INCLUDING ALL COVID-19 PATIENTS (HOSPITALISED AND IN THE COMMUNITY)</b> |  |  |  |  |  |
| <b>Boulle et al, (2020)</b> [18]   | Multi centre: Western Cape, South Africa | Prospective cohort study of 540,552 PLWH (3978 confirmed COVID-19) & 2,920,380 HIV-negative adults (18,330 confirmed COVID-19)   | 34% male, median age 20-39 years. No data on proportions by ethnicity, ART, or any co-morbidity. 7.6% with VL >1000 copies/ml or CD < 200 cells/ $\mu$ L, 34.7% with VL unknown in past 15 months. | 115 (2.1/10,000) COVID-19 deaths in PLWH vs 510 (1.7/10,000) in adults without HIV. Adjusted for age & sex, aHR: 1.97; 95% CI: 1.59-2.45. Adjusted for age, sex & co-morbidities: aHR: 2.14; 95% CI: 1.70-2.70 <sup>1</sup> .  | JBIC = 11. Risk of confounding by socio-economic status & BMI.                                 |
| <b>Bhaskaran et al</b> [27], (2020)  | Multi centre, United Kingdom             | Retrospective population-based cohort analysis of primary care data of 27,480 PLWH and 17,255,425 adults without HIV. Numbers diagnosed with COVID-19 not presented.         | 65% male, median age 40-55 years, 46.2% White, 5.1% Mixed, 4.3% South Asian, 26% Black, 2.3% Other. No data on proportions with any co-morbidity, or by ART, CD4+ count, viral suppression         | 25 (9.1/10,000) COVID-19 deaths in PLWH vs 14,875 (8.6/10,000) in adults without HIV. Adjusted for age & sex, aHR: 2.90, 95% CI: 1.96-4.30. Adjusted for age, sex & co-morbidities, aHR 2.30; 95% CI: 1.55-3.41 <sup>2</sup> . | JBIC = 11. Small number of outcomes amongst PLWH therefore possible overfitting of model.      |
| <b>Hadi et al</b> [10], 2020   | Multi centre, United States              | Retrospective cohort study amongst people with SARS-CoV-2 infection comparing 404 PLWH with 49,763 adults without HIV (including matched cohort of 404 adults <sup>3</sup> ) | 71% male, mean age 48.1, 50% Black or African American, 34% White, 13% Latinx, 3% Asian. No data on proportions with any co-morbidity. 70% on ART, no data on CD4 count or VL.                     | 20 (4.95%) COVID-19 deaths in PLWH vs 1585 (3.19%, risk ratio [RR] 1.55, 95% CI: 1.01 – 2.39) in unmatched cohort, and 15 (3.71%, RR 1.33, 95% CI: 0.69 – 2.57) in matched cohort.   | JBIC = 10. Unclear how COVID-19 diagnosed. 1:1 matching may result in underpowered analysis.   |
| <b>del Amo et al, (2020)</b> [11]  | Multi centre, 60 Spanish HIV clinics     | Cohort study of 236 PLWH receiving ART with COVID-19, recruited from 77,590 patients of HIV clinics  | 75% male, median age 50-59 years. 100% receiving ART. No data on ethnicity, CD4 count, viral load or other co-morbidities. 64% hospitalised, 6% in ICU.  | 20 (8%) PLWH died, giving age and sex standardised risk of death of 3.7/10,000 vs 2.1/10,000 in general Spanish population   | JBIC = 7. Comparison group from a different population. Confounding factors not accounted for. |

|                                     |                                       |   |   |   |   |
|-------------------------------------|---------------------------------------|---|---|---|---|
| <b>Miyashita et al [19], 2020</b>   | Multi-centre:<br>New York,<br>US      | Cohort study of people with SARS-CoV-2 infection comparing 161 PLWH to 8751 people without HIV  | 78% male, median age 51-65 years. No data on ethnicity, ART, CD4, VL, or proportion with <b>any</b> comorbidity   | 23 (14%) PLWH died vs 1235 (14%) without HIV (but in age <50 years, PLWH had higher risk of death (RR 4.36, 95% CI 1.43–13.3)                                 | JBI C = 7. Confounding factors not accounted for. Insufficient follow up time for some patients.                              |
| <b>Ho et al [20], (2020)</b>        | Multi-centre,<br>New York,<br>US      | Case series of 93 PLWH who presented to ED with positive SARS-CoV-2 RT-PCR test   | 72% male, median age 58 years, 40.9% Black, 31.2% Hispanic/Latinx. 96% on ART, 84% VL <50 copies/ml, median CD4 554 cells/μL.                             | 19 (20.4%) PLWH died, no mortality comparison given   | JBI CS = 8. Deaths amongst those not admitted not recorded.   |
| <b>Di Biagio et al [21], 2020</b>   | Multi-centre,<br>Italy                | Case series of 69 PLWH who were diagnoses with SARS-CoV-2 infection   | 72% male, median age 50-55, 86% Caucasian, 100% on ART, 88% VL < 50 copies/ml, median CD4 580-600 cells/μL.   | 7 (10.8% of those with known outcomes) PLWH died, no mortality comparison given   | JBI CS = 5. Not clear if participating centres identified SARS-CoV-2 cases systematically. Statistics unclear.                |
| <b>Maggiolo et al [22], (2020)</b>  | Single-centre,<br>Bergamo,<br>Italy   | Cohort study of 55 PLWH with suspected/confirmed COVID-19 vs 69 asymptomatic PLWH who tested negative for SARS-CoV-2 (RT-PCR or serology) | 80% male, median age 54 (IQR: 49-58), 100% receiving ART, 98% VL <50 copies/ml, median last CD4 count 904 cells/μL, 51% with any co-morbidity.            | 4 (7.2%) PLWH died, no mortality comparison given   | JBI C = 6. Follow up unclear. Confounding factors not accounted for. Sample size not large enough for multivariable analysis. |
| <b>Etienne et al [23], (2020)</b>   | Single centre,<br>Paris, France       | Case series of 54 PLWH with symptoms or were hospitalised with COVID-19   | 61.1% male, median age 54, 100% on ART, 96.2% VL < 40 copies/mL, median CD4 count 583 cells/mm <sup>3</sup> , 44.6% Sub Saharan African origin            | 1 (1.9%) PLWH died, no mortality comparison given   | JBI CS = 3. COVID-19 case definition and disease severity not defined. Short follow up time                                   |
| <b>Inciarte et al [24], (2020)</b>  | Single centre,<br>Barcelona,<br>Spain | Cohort study of 5683 PLWH in of whom 53 PLWH had confirmed or suspected COVID-19  | 85% male, median age 44, median last CD4 cells/mm <sup>3</sup> 618 (IQR: 449-834), 96% on ART   | 2 (4%) PLWH died, no mortality comparison given   | JBI C = 7. COVID-19 case definition unclear. Duration of follow-up unclear. Confounding not accounted for.                    |
| <b>Gervasoni et al, (2020) [25]</b> | Single centre:<br>Milan, Italy        | Case series of 47 PLWH with suspected/confirmed COVID-19  | 74% male, median age 52 years, no ethnicity data. 100% receiving ART, median CD4 count 636 cells/μL, 93.6% with undetectable VL. 64% with ≥1 comorbidity. | 2 PLWH died (4.2% of cohort, 15.4% of those hospitalised with COVID-19) , vs 17% died among 502 HIV-negative patients admitted with COVID-19 at same hospital | JBI CS = 7. Comparison group from a different population. Length of follow-up unclear. Confounding factors not accounted for. |

|  |   |  |   |  |   |
|--|---|--|---|--|---|
| <b>Huang et al</b><br>[26], (2020)                           | Multi-centre:<br>Wuhan City,<br>China           | Cohort study 6001 PLWH of whom <b>35 were</b> diagnosed with COVID-19  | 90% male, median age 37 years, no data on ethnicity. 92% on ART, median CD4 count 200-499 cells/ $\mu$ L, 66% VL < 20 copies/mL.  | 2 (5.7%) PLWH with COVID-19 died vs 3869/50333 (7.69%) of general population of Wuhan with COVID-19  | JBIC = 5. Comparison group from a different population. Follow-up not clear. Confounding not accounted for.                 |
| <b>Härter et al</b><br>[12], (2020)                          | Multi centre:<br>12 German<br>HIV centres       | Case series of <b>33</b> PLWH with confirmed COVID-19  | 91% male, median age 48 years, no ethnicity data. 100% receiving ART, overall median CD4 count 670 cells/ $\mu$ L, 94% virally suppressed, 60% with $\geq 1$ comorbidity  | 3 PLWH died (9.1%) vs 3.7% mortality in general COVID19 positive population in Germany   | JBIC = 7. Comparison group from a different population and confounding not accounted for. Not all patients with an outcome. |
| <b>STUDIES INCLUDING ONLY HOSPITALISED COVID-19 PATIENTS</b> |   |  |   |  |   |
| <b>Geretti et al</b><br>[28], (2020)                         | Multi centre:<br>207 UK<br>hospitals            | Prospective cohort study of people hospitalised with suspected/confirmed COVID-19. <b>115</b> PLWH vs 47,424 HIV-negative adults                                 | 66% male, median age 49-61 years. White (41.5%), Black (45.3%), Asian (0.9%), Other (12.3%). 74% $\geq 1$ comorbidity. No data on proportions by ART, CD4 or VL   | 26 PLWH died (23%) vs 13,955 (29%) in adults without HIV. Adjusted for age & sex, aHR: 1.39; 95% CI: 0.93-2.08. Adjusted for age, sex and co-morbidities, aHR: 1.63; 95% CI: 1.07-2.48, $p=0.02^4$ . | JBIC = 9. 10% with missing outcome data.  |
| <b>Sigel et al</b><br>[13], (2020)                           | Multi centre:<br>5 hospitals<br>New York,<br>US | Cohort study of <b>88</b> PLWH hospitalised with laboratory confirmed COVID-19 compared to matched cohort of 405 hospitalised HIV-negative adults <sup>5</sup> . | 78% male, median age 45-67 years. Ethnicity: White (19%), Black, (40%), Hispanic (30%), Other (11%). No data on proportions with any co-morbidity. 100% on ART, 58% CD4 >200 cells/ $\mu$ L, 81% VL <50 copies/ $\mu$ L | 18 (21%) COVID-19 deaths in PLWH versus 81 (20%) in adults without HIV   | JBIC = 6. Follow up not complete for all patients. Matched on limited number of confounders. Potential over-adjustment.     |
| <b>Vizcarra et al</b> , [14], (2020)                         | Single centre:<br>Madrid                        | Case series of <b>51</b> PLWH with suspected/confirmed COVID-19  | 84% male mean age 53.3 years, 88% white ethnicity. 100% receiving ART, median CD4 565 cells/ $\mu$ L, 98% virally suppressed, 63% with $\geq 1$ comorbidity.  | 2 PLWH died (4%) vs 20% amongst general population admitted to nearby hospital with COVID-19.  | JBIC = 7. Comparison group from different population. COVID-19 case definition unclear. Not all cases completed follow up.  |

|  |  |   |   |  |  |
|--|--|---|---|--|--|
| <b>Shalev et al</b><br>[15], (2020)            | Single centre:<br>New York,<br>US                  | Case series of <b>31</b> PLWH hospitalised for<br>COVID-19 at a large tertiary care medical<br>centre in New York City.   | 77% male, mean age 60.7 years, 52% black, 29% Hispanic,<br>9% white. 100% receiving ART, median CD4 396 cells/ $\mu$ L,<br>100% virally suppressed, 71% with $\geq$ 1 comorbidity | 8 PLWH died (27.6%), no mortality comparison<br>given                  | JBI CS = 8. Not all cases completed<br>follow up.                          |
| <b>Karmen-<br/>Tuohy et al</b><br>[16], (2020) | Multi centre:<br>4 hospitals in<br>New York,<br>US | Cohort study of <b>21</b> PLWH hospitalised with<br>confirmed COVID-19 compared to a matched<br>cohort <sup>6</sup> of 42 HIV-negative patients (selected<br>from 2617 non-HIV patients with COVID-19<br>at same centres) | 90.5% male, mean age 60 years, 24% African American,<br>38% White, 38% Other. 100% receiving ART, median<br>CD4+ 298 cells/ $\mu$ L, 71% VL <50 copies/mL                         | 6 PLWH died (28.6%) vs 10 (23.8%) in HIV-<br>negative cohort (p=0.682) | JCI C = 11.  |
| <b>Childs et al</b><br>[17], (2020)            | Single centre:<br>London, UK                       | Case series of <b>18</b> PLWH hospitalised with<br>confirmed COVID-19.  | 67% male, median age 52, 94% black ethnicity. 100% on<br>ART, median CD4 395 cells/ $\mu$ L, 94% virally suppressed   | 5 PLWH died (29%), no mortality comparison<br>given                    | JCI CS = 6. Time period of<br>enrolment and follow up time not<br>defined. |

\* Joanna Briggs Institute [JBI] Cohort Study [C] or Case Series [CS] checklist items completed, with comment. See Tables S2 and S3 for full scores.

1. Adjusted for age, sex, diabetes, tuberculosis history and other co-morbidities (hypertension, kidney disease, lung disease)
  2. Adjusted for age, sex, deprivation, ethnicity, obesity, smoking, and presence of comorbidities (hypertension, chronic respiratory disease, chronic cardiac disease, diabetes, non-haematological cancer, haematological cancer, chronic liver disease, stroke, dementia, other neurological disease, reduced kidney function, organ transplant, asplenia, rheumatoid arthritis, lupus, psoriasis, or other immunosuppressive disorders)
  3. Matched on age, gender, ethnicity, smoking, body mass index, diabetes, hypertension and chronic lung diseases
  4. Adjusted for age, sex, ethnicity, baseline date, indeterminate/probable hospital acquisition of COVID-19, ten co-morbidities, and disease severity at presentation
  5. Matched on age, sex, race/ethnicity and week of SARS-CoV-2 infection
  6. Matched on age, gender, body mass index, smoking, co-morbidities (chronic kidney disease, hypertension, asthma, chronic obstructive pulmonary disease, heart failure) and admission date, all from same centre
- ART = antiretrovirals, PLWH = people living with HIV, VL = viral load,

*Table 2: Summary of studies reporting outcomes by ART regimen and other risk factors for adverse COVID-19 outcomes amongst people living with HIV*

| STUDY   | INFLUENCE OF ART REGIMENS  | OTHER RISK FACTORS AMONG PLWH  |
|---|--|--|
| <b>Boulle et al, (2020)</b><br>[18]n=3978   | Lower mortality in patients on TDF vs abacavir/zidovudine (aHR: 0.42; 95% CI: 0.22;0.78)   | 601 patients had CD4 count measured during episode of C-19. Higher mortality associated with CD4 counts <200 cells/ $\mu$ L (n=70) vs $\geq$ 350 cells/ $\mu$ L (aHR 1.97; 95% CI 1.14-3.40). Direction of causality unclear. No difference in hazard of C-19 death by HIV VL (aHR vs HIV-negative: 2.61 (95% CI: 1.98-3.43) for VL < 1000 copies/mL; 3.35 (95% CI: 1.38-6.12) for VL $\geq$ 1000 copies/mL or CD4 <200 cells/ $\mu$ L). |
| <b>Bhaskaran et al [27], (2020)</b><br><br><b>Number of PLWH &amp; COVID-19 not presented</b> | N/A  | PLWH of Black ethnicity had higher risk of COVID-19 mortality (aHR 3.80, p for interaction 0.045). No data on outcomes by CD4 or VL.   |
| <b>del Amo et al, (2020) [11]</b><br><br><b>n=236</b>   | Lowest risk for C-19 diagnosis (16.9% [95% CI: 10.5 - 25.9] & hospitalisation (10.5 [95% CI: 5.6 - 17.9] ) in PLWH receiving TDF/FTC compared to other ART regimens (e.g. ABC/3TC 28.3% [95% CI: 21.5 - 36.7] and 23.4% [95% CI: 17.2 - 31.1] respectively). | Higher crude risk of C-19 death amongst older PLWH (70-79 years = 26.6/10,000, 95% [CI 10.7–54.9] vs 50-59 years 2.2/10,000 [95% CI 10.7-54.9]). No difference by sex.   |
| <b>Ho et al [20], (2020)</b><br><br><b>n=93</b>   | No significant difference in TDF use between PLWH with C-19 who survived and died (73.6% vs 55.5%, p=0.15).  | No significant differences in obesity, CD4 counts or HIV VL between PLWH with C-19 who survived and died   |
| <b>Di Biagio et al [21], 2020</b><br><br><b>n=69</b>  | No stat. sig. association between risk of hospitalisation and ART regimens   | Hospitalised PLWH were slightly older (p=0.047). No association between most recent VL or CD4 count and hospitalisation.   |
| <b>Maggiolo et al [22], (2020)</b><br><br><b>n=55</b>   | No difference in TDF use amongst PLWH with C-19 (60%) vs without C-19 (60.8%)  | 4 PLWH with C-19 who died had lower last CD4 count (median 514 cells/ $\mu$ L) than the 51 PLWH who survived (median 913 cells/ $\mu$ L).  |
| <b>Etienne et al [23], (2020)</b><br><br><b>n=54</b>  | No stat. sig. difference between ART regimen and C-19 severity   | No stat. sig. association between CD4 counts or VL < 40 copies/ml and C-19 severity  |
| <b>Inciarte et al [24], (2020)</b><br><br><b>n=53</b>   | No associations between ART regimen and C-19 severity  | No association between latest CD4 count and C-19 severity  |
| <b>Huang et al [26], 2020</b><br><br><b>n=35</b>  | N/A  | Older age and ART discontinuation associated with C-19 infection. No association between latest CD4 count or VL and C-19 infection.  |



|   |   |   |
|---|---|---|
| <b>Geretti et al [28], (2020)</b><br><b>n=115</b>     | N/A   | Age, obesity and diabetes were associated with C-19 death amongst PLWH.   |
| <b>Sigel et al [13], (2020)</b><br><b>n=88</b>        | PLWH who survived were more likely to have been treated with NRTIs than those PLWH who died (99% v 89%, p=0.04) in univariate analysis. No difference in outcomes for other classes of ART. | No association between comorbidities, latest CD4 count or VL and C-19 death.  |
| <b>Vizcarra et al, [14], (2020)</b><br><b>n=51</b>    | Increased TAF use in PLWH with C-19 (37/51, 73%), vs PLWH without COVID-19 (38%, p=0.0036)  | PLWH with C-19 were significantly more likely to have comorbidities (63% vs 38%, P=0.00059), and had higher median BMI (25.5 kg/m <sup>2</sup> vs 23.7 kg/m <sup>2</sup> , P=0.021) compared to 1288 PLWH without C-19. No association between CD4+ T cell count and SARS-CoV-2 infection or adverse C-19 outcomes. |
| <b>Shalev et al [15], (2020)</b><br><b>n=31</b>       | 7/8 (88%) PLWH who died from C-19 used TAF/TDF vs 10/23 (43%) of those who survived   | N/A   |
| <b>Karmen-Tuohy et al [16], (2020)</b><br><b>n=21</b> | N/A   | No association between most recent CD4 count and mortality (OR 0.996, 95% CI: 0.992 to 1.11)  |
| <b>Childs et al [17], (2020)</b><br><b>n=18</b>       | More common use of protease inhibitor-containing ART regimens among PLWH with C-19 (OR, 2.43, 95% CI, .94–6.29)   | PLWH hospitalised with C-19 were more likely to be of black ethnicity (OR: 12.22, 95% CI: 1.62-92.00), and had lower median CD4+ cell counts (395 vs 573, P=0.03)   |


3TC = lamivudine, ABC = abacavir, FTC = emtricitabine, ART = antiretroviral therapy, BMI = body mass index, C-19 = COVID-19, OR = odds ratio, PLWH = people living with HIV, stat. sig. = statistically significant, TAF = tenofovir alafenamide, TDF = tenofovir disoproxil fumarate, VL = viral load

## Figures

**Figure 1: PRISMA Flow diagram to show studies identified and included in a systematic meta-analysis of outcomes of COVID-19 in people living with HIV (PLWH)**

**Figure 2 Meta-analysis of the effect of HIV on risk of COVID-19 death.**

Figure 2 caption: Country; UK = United Kingdom, US = United States of America, ZA = South Africa. HIV+ and HIV- refers to people with and without HIV. C19 refers to those with COVID-19. The denominators (N) refer to the original population where reported: A cohort of people diagnosed with HIV and the wider general population without HIV. Not all studies reported this information. Results are reported as hazard ratios (HR) with 95% confidence intervals (95%CI).



| Study  | Country | N      | HIV+<br>C19 | Death | N        | HIV-<br>C19 | Death | Hazard Ratio | HR          | 95%-CI                | Weight        |
|--|---------|--------|-------------|-------|----------|-------------|-------|--------------|-------------|-----------------------|---------------|
| Boulle   | ZA      | 540552 | 3978        | 115   | 2920380  | 18330       | 510   |              | 2.14        | (1.70 to 2.70)        | 47.8%         |
| Bhaskaran  | UK      | 27480  | n/a         | 25    | 17255425 | n/a         | 14857 |              | 2.30        | (1.55 to 3.42)        | 20.6%         |
| Hadi   | US      | n/a    | 404         | 20    | n/a      | 404         | 15    |              | 1.33        | (0.69 to 2.57)        | 8.2%          |
| Geretti  | UK      | n/a    | 115         | 26    | n/a      | 47424       | 13955 |              | 1.63        | (1.07 to 2.48)        | 18.6%         |
| Karmen-Tuohy   | US      | n/a    | 21          | 6     | n/a      | 42          | 10    |              | 1.20        | (0.50 to 2.85)        | 4.8%          |
| <b>Random effects model</b>                                  |         |        |             |       |          |             |       |              | <b>1.93</b> | <b>(1.59 to 2.34)</b> | <b>100.0%</b> |
| Heterogeneity: $I^2 = 11\%$ , $\tau^2 = 0.0065$ , $p = 0.34$ |         |        |             |       |          |             |       |              |             |                       |               |

